Sign inSign up
Sign upSign in

Research · Trials

The clinical trials,
by compound.

Every registered trial we track for our compounds, pulled from ClinicalTrials.gov. Filter by compound, status, and phase — or download the full directory as data.

368 tracked trials · 163 active ·62 with posted results · Source: ClinicalTrials.gov API v2 · Updated 2026-07-12 · Public domain (U.S. Government work)

GLP-1 trials dataset →Peptide trials dataset →

368 of 368 trials shown

TrialCompoundsPhaseStatusEnroll.Start
Metabolic Surgery for Atrial Fibrillation EliminationNCT07027969 · Ali AminianLiraglutideDulaglutidePhase 4Not yet recruiting1002026-11-01
Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusNCT07677891 · ProGen. Co., Ltd.DulaglutidePhase 2Not yet recruiting602026-10
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336 · Eli Lilly and CompanyDulaglutideOrforglipronPhase 3Not yet recruiting1702026-09
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNCT07357740 · Novo Nordisk A/SSemaglutideCagrilintidePhase 2Withdrawn02026-08-27
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 · Novo Nordisk A/SCagrilintidePhase 3Not yet recruiting802026-08-04
An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use DisorderNCT07693608 · University of Texas Southwestern Medical CenterTirzepatidePhase 2Not yet recruiting452026-08-01
Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA TrialNCT07676331 · Universitaire Ziekenhuizen KU LeuvenTirzepatidePhase 2Not yet recruiting1682026-08-01
Tirzepatide in the Treatment of Cannabis Use DisorderNCT07671248 · McMaster UniversityTirzepatidePhase 3Not yet recruiting152026-08-01
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese ParticipantsNCT07671391 · Shanghai Zhongshan HospitalTirzepatidePhase 2Not yet recruiting602026-08
GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid ObesityNCT07668765 · Gazi UniversityTirzepatide—Not yet recruiting1002026-08
Imaging in Semaglutide StudyNCT07695454 · The Cleveland ClinicSemaglutide—Not yet recruiting102026-07-15
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular CancerNCT07627191 · University of ArizonaSemaglutideEARLY_Phase 1Not yet recruiting302026-07-10
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial CancerNCT07349641 · National Cancer Institute (NCI)TirzepatidePhase 2Not yet recruiting552026-07-06
Free Fatty Acid Effects In Type 2 DiabetesNCT07677995 · University of UlsterSemaglutide—Enrolling by invitation602026-07
Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes MellitusNCT07563699 · Mapi Pharma Ltd.SemaglutidePhase 1/Phase 2Not yet recruiting242026-07
Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide ImplantNCT07430059 · Vivani Medical, IncSemaglutidePhase 1Not yet recruiting202026-07
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol SecretionNCT07573163 · Alaa SadaTirzepatidePhase 2Not yet recruiting342026-07
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307 · Eli Lilly and CompanyOrforglipronPhase 3Not yet recruiting1302026-07
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766 · Novo Nordisk A/SSemaglutideCagrilintidePhase 3Withdrawn02026-06-22
Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial FibrillationNCT07382024 · National Taiwan University HospitalTirzepatide—Not yet recruiting2002026-06-16
Brain Plasticity and GLP-1 Receptor Agonist Treatment for ObesityNCT07021937 · University of Colorado, DenverSemaglutidePhase 3Not yet recruiting1202026-06-15
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese ParticipantsNCT07673900 · Terrestrial Bio, Inc.SemaglutidePhase 1Recruiting622026-06-15
Tirzepatide in MetALDNCT07046819 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)TirzepatidePhase 2Recruiting1202026-06-11
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With ObesityNCT07639021 · Novo Nordisk A/SSemaglutidePhase 2Recruiting2302026-06-09
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer SurvivorsNCT07257484 · Weill Medical College of Cornell UniversityTirzepatidePhase 4Recruiting302026-06-08
Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical ClockNCT07444073 · National University of SingaporeSemaglutideTirzepatide—Not yet recruiting4402026-06-01
Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and ReinitiationNCT07387796 · The University of Texas at DallasTirzepatide—Recruiting402026-06
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsNCT07607587 · Novo Nordisk A/SCagrilintidePhase 1Recruiting1142026-05-29
Genetic, Microbiological and Behavioral Factors in ObesityNCT07650149 · Jan Kochanowski UniversityTirzepatide—Recruiting2002026-05-23
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDNCT07527910 · Regeneron PharmaceuticalsTirzepatidePhase 2Recruiting2042026-05-22
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 · Novo Nordisk A/SSemaglutideCagrilintidePhase 3Recruiting25002026-05-21
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)NCT07559500 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)TirzepatidePhase 1Recruiting1762026-05-20
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052 · Novo Nordisk A/SCagrilintidePhase 1Active not recruiting502026-05-20
Phase 3 Study of LUM-201 in Children With Growth Hormone DeficiencyNCT06948214 · Lumos PharmaMK-677Phase 3Recruiting1502026-05-20
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityNCT07597018 · Novo Nordisk A/SCagrilintidePhase 1Recruiting2342026-05-18
Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial InfarctionNCT07586865 · Beijing Northland Biotech. Co., Ltd.Thymosin Beta-4Phase 2Not yet recruiting1892026-05-18
Tirzepatide Titration to Reduce Side Effects in Individuals With ObesityNCT07574723 · Dasman Diabetes InstituteTirzepatide—Recruiting682026-05-15
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral SclerosisNCT06726577 · Talengen Institute of Life Sciences, Shenzhen, P.R. China.LiraglutidePhase 1/Phase 2Recruiting602026-05-10
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.NCT07301437 · The Fourth Affiliated Hospital of Zhejiang University School of MedicineLiraglutidePhase 4Not yet recruiting1202026-05-01
Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseaseNCT07537088 · First Affiliated Hospital of Wannan Medical CollegeDulaglutidePhase 4Not yet recruiting4682026-05
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityNCT07557953 · Novo Nordisk A/SCagrilintidePhase 1Recruiting1202026-04-30
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple SclerosisNCT07497399 · Johns Hopkins UniversityExenatidePhase 2Recruiting1202026-04-28
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.NCT07653412 · National and Kapodistrian University of AthensSemaglutideTirzepatide—Recruiting2202026-04-22
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesNCT07415954 · Novo Nordisk A/SSemaglutidePhase 2Recruiting2702026-04-17
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)NCT07527195 · Novo Nordisk A/SCagrilintidePhase 1Recruiting1002026-04-10
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaNCT07107334 · University of FloridaLiraglutideOrforglipronPhase 2Recruiting202026-04-07
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight LossNCT07446998 · Veru Inc.SemaglutidePhase 2Recruiting2002026-03-26
A Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846 · Alnylam PharmaceuticalsTirzepatidePhase 1/Phase 2Recruiting1562026-03-02
Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal TransplantationNCT07678073 · University of GaziantepMOTS-c—Recruiting682026-03-01
Evaluation of Facial and Neck Skin Laxity With SofWave Treatment in Adults Initiating Tirzepatide for Weight LossNCT07685834 · Sofwave Medical LTDTirzepatide—Active not recruiting302026-02-27
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightNCT07467447 · Hudson BiotechRetatrutidePhase 2Recruiting3002026-02-15
The Evira Study: Additional Support During Obesity TreatmentNCT06836284 · Karolinska InstitutetLiraglutide—Recruiting402026-02-13
Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.NCT07619508 · Brigham and Women's HospitalSemaglutideTirzepatide—Completed1000002026-02-10
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNCT07411560 · Novo Nordisk A/SCagrilintidePhase 1Recruiting1002026-02-09
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVDNCT07487363 · Hudson BiotechTB-500Thymosin Beta-4Phase 1/Phase 2Recruiting802026-02-05
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.NCT07417631 · Brigham and Women's HospitalDulaglutide—Completed3000002026-02-03
BPC 157 for Acute Hamstring Muscle Strain RepairNCT07437547 · Hudson BiotechBPC-157Phase 2Recruiting1202026-02-02
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)NCT07481734 · Hudson BiotechTesamorelinPhase 2Recruiting1202026-02-02
MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/ObesityNCT07505745 · Hudson BiotechMOTS-cPhase 2Recruiting1202026-02-02
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)NCT07417618 · Brigham and Women's HospitalSemaglutideTirzepatideDulaglutide—Completed600002026-01-27
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)NCT07390110 · Brigham and Women's HospitalSemaglutide—Active not recruiting256642026-01-24
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightNCT07357415 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting6002026-01-24
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular RiskNCT07619495 · Brigham and Women's HospitalSemaglutideDulaglutide—Completed1200002026-01-20
A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes MellitusNCT07347080 · The First Affiliated Hospital of Henan University of Science and TechnologyExenatideEARLY_Phase 1Recruiting92026-01-20
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 · Novo Nordisk A/SCagrilintidePhase 3Recruiting4602026-01-08
Estimating the Impact of Obesity Medications on Clinical and Economic OutcomesNCT07640139 · Indiana UniversityLiraglutide—Enrolling by invitation1250002026-01-01
A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusNCT07313813 · Eli Lilly and CompanyDulaglutidePhase 1Active not recruiting202025-12-29
Role of GLP1 RA Dulaglutide on Severe Intracranial AtherosclerosisNCT07282041 · National University of SingaporeDulaglutidePhase 2/Phase 3Recruiting1302025-12-17
Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric RetentionNCT07276763 · Fudan UniversityDulaglutide—Not yet recruiting165092025-12-10
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)NCT07241390 · Eli Lilly and CompanyOrforglipronPhase 3Recruiting71402025-12-01
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)NCT07247084 · Eli Lilly and CompanyTirzepatidePhase 4Recruiting30002025-11-24
A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting2502025-11-17
Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIVNCT06935838 · University of HawaiiTirzepatidePhase 2Completed122025-11-12
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)NCT07225816 · Novo Nordisk A/SLiraglutidePhase 1Recruiting752025-11-07
Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNCT07220642 · Novo Nordisk A/SCagrilintidePhase 3Active not recruiting3002025-11-05
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759 · Novo Nordisk A/SCagrilintidePhase 3Active not recruiting3302025-11-05
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseNCT07223593 · Eli Lilly and CompanyOrforglipronPhase 3Recruiting12052025-10-31
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 · Eli Lilly and CompanyTirzepatideRetatrutidePhase 3Recruiting45002025-10-15
A Phase 3 Study of HS-20094 in Patients With T2DMNCT07156539 · Jiangsu Hansoh Pharmaceutical Co., Ltd.DulaglutidePhase 3Not yet recruiting5462025-09-30
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884 · Eli Lilly and CompanyOrforglipronPhase 3Recruiting10002025-09-30
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086 · Novo Nordisk A/SCagrilintidePhase 1Recruiting802025-09-26
Study of Tirzepatide for Recovery and Alcohol Use ManagementNCT06727331 · Brigham and Women's HospitalTirzepatidePhase 2Recruiting202025-09-15
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)NCT07188545 · Ohio State UniversityDulaglutideExenatide—Active not recruiting232800002025-09-15
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471 · Eli Lilly and CompanyOrforglipronPhase 3Recruiting8002025-09-15
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 DiabetesNCT07112872 · Hoffmann-La RocheSemaglutidePhase 2Active not recruiting2402025-08-19
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With ObesityNCT07091500 · Washington University School of MedicineSemaglutide—Recruiting402025-08-11
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes MellitusNCT07319286 · Ain Shams UniversityDulaglutidePhase 1/Phase 2Enrolling by invitation502025-08-04
Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist TherapyNCT06903923 · University of VirginiaLiraglutidePhase 2Recruiting1202025-07-31
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIVNCT06554717 · Massachusetts General HospitalSermorelinTesamorelinPhase 2Recruiting1002025-07-10
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099 · Eli Lilly and CompanyTirzepatidePhase 3Recruiting2902025-06-26
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyNCT06937086 · Eli Lilly and CompanyTirzepatidePhase 3Recruiting3502025-06-26
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and OsteoarthritisNCT07225829 · 4Moving BiotechLiraglutidePhase 2Recruiting1292025-06-17
The Role of the Amylin Analogue Cagrilintide in Bone MetabolismNCT07010432 · Novo Nordisk A/SCagrilintidePhase 1Recruiting1442025-06-12
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaNCT06982846 · Eli Lilly and CompanyRetatrutidePhase 1Completed802025-06-06
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667 · Novo Nordisk A/SCagrilintidePhase 3Active not recruiting6092025-06-03
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusNCT06982859 · Eli Lilly and CompanyRetatrutidePhase 1Recruiting952025-06-02
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093 · Eli Lilly and CompanyRetatrutidePhase 3Recruiting5862025-05-29
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.NCT06851962 · Fundación para la Investigación del Hospital Clínico de ValenciaDulaglutidePhase 4Active not recruiting5042025-05-26
Tirzepatide vs Liraglutide in BoneNCT07094568 · National and Kapodistrian University of AthensLiraglutide—Recruiting722025-05-23
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesNCT06972472 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting6002025-05-19
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting12002025-05-15
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting6002025-05-15
A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes MellitusNCT06937203 · Arrowhead PharmaceuticalsTirzepatidePhase 1/Phase 2Recruiting1502025-05-09
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)NCT07029009 · MansaLiraglutidePhase 2Recruiting502025-05-08
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical PracticeNCT07055607 · Novo Nordisk A/SSemaglutide—Enrolling by invitation12502025-05-01
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or MetforminNCT07109700 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.DulaglutidePhase 2Recruiting2162025-04-30
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting4872025-04-30
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting9742025-04-30
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting4872025-04-30
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideNCT06897475 · Eli Lilly and CompanySemaglutideTirzepatidePhase 2Recruiting2402025-03-28
Effect of Tirzepatide on Brown Adipose Tissue in ObesityNCT06893211 · University Medical Centre LjubljanaTirzepatidePhase 2Completed342025-03-18
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)NCT06864026 · Eli Lilly and CompanyTirzepatidePhase 4Recruiting2002025-03-06
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting6432025-03-05
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or OverweightNCT06824051 · Eli Lilly and CompanyOrforglipronPhase 1Completed1202025-02-17
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNCT06780449 · Novo Nordisk A/SCagrilintidePhase 3Active not recruiting4002025-02-10
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsNCT06808802 · Eli Lilly and CompanyRetatrutidePhase 1Completed302025-02-03
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 · Novo Nordisk A/SCagrilintidePhase 2Active not recruiting1422025-01-29
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)NCT06739122 · Eli Lilly and CompanyDulaglutidePhase 3Recruiting552025-01-10
Tirzepatide-Based Prehabilitation Before Elective Ventral and Incisional Hernia Repair in Patients With ObesityNCT07638592 · Azienda Sanitaria Locale Napoli 2 NordTirzepatide—Completed912025-01-01
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor AgonistsNCT07325435 · MaryAnn BanerjiLiraglutideDulaglutidePhase 4Active not recruiting602024-12-21
Assessment of Safety, Tolerability and Drug Levels of Exenatide ImplantNCT05670379 · Vivani Medical, IncExenatidePhase 1Completed242024-12-20
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy ParticipantsNCT06704763 · Eli Lilly and CompanyOrforglipronPhase 1Completed272024-12-06
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusNCT06700538 · Arrowhead PharmaceuticalsTirzepatidePhase 1/Phase 2Recruiting1802024-12-04
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityNCT06716307 · Novo Nordisk A/SCagrilintidePhase 1Completed182024-12-02
Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent ThalassemiaNCT07370922 · Ain Shams UniversityDulaglutidePhase 2Completed802024-11-22
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939 · Eli Lilly and CompanyOrforglipronPhase 3Recruiting1502024-11-18
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549 · Eli Lilly and CompanyOrforglipronPhase 3Recruiting1252024-11-18
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411 · Novo Nordisk A/SCagrilintidePhase 3Active not recruiting10232024-11-05
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting8002024-11-01
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT06779929 · Brigham and Women's HospitalDulaglutide—Completed700002024-11-01
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting6002024-10-22
Food (Poly)Phenol Metabotypes and Beta-cell Mass and Function.NCT06888167 · Azienda Ospedaliero-Universitaria di ParmaExenatide—Recruiting402024-10-14
Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective SurgeryNCT06500143 · Ciusss de L'Est de l'Île de MontréalDulaglutide—Completed942024-10-09
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverNCT05202353 · Boehringer IngelheimSemaglutidePhase 1Recruiting302024-10-01
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular RiskNCT07096063 · Brigham and Women's HospitalDulaglutide—Completed8871322024-10-01
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims DataNCT07088718 · Brigham and Women's HospitalDulaglutide—Completed446712024-10-01
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightNCT06588283 · Eli Lilly and CompanyTirzepatidePhase 3Completed2812024-09-30
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering DrugsNCT05663515 · AstraZenecaExenatide—Recruiting240002024-09-30
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 AgonistsNCT06640972 · Response PharmaceuticalsSemaglutideTirzepatidePhase 2Completed682024-09-27
Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2NCT06396416 · Western University, CanadaSemaglutidePhase 4Recruiting602024-09-26
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)NCT06584916 · Eli Lilly and CompanyOrforglipronPhase 3Completed3762024-09-13
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in BangladeshNCT06449235 · Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic DisordersExenatidePhase 4Not yet recruiting9382024-09
Exenatide For Reducing the Reinforcing Effects of CocaineNCT06252623 · Christopher D. VerricoExenatidePhase 1Withdrawn02024-08-01
Holding vs. Continuing Incretin-based Therapies Before Upper EndoscopyNCT06533527 · The Cleveland ClinicDulaglutidePhase 4Completed692024-07-31
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminNCT06257966 · Beijing Dongfang Biotech Co., Ltd.DulaglutideExenatidePhase 3Active not recruiting6002024-07-17
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM PatientsNCT06254014 · Beijing Dongfang Biotech Co., Ltd.ExenatidePhase 3Active not recruiting2702024-07-10
Risk Factors Affect Weight Loss Outcomes After Treatment.NCT06482411 · E-DA HospitalLiraglutide—Completed36022024-06-27
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightNCT06388187 · Novo Nordisk A/SCagrilintidePhase 3Completed3002024-06-24
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)NCT06439277 · Eli Lilly and CompanyTirzepatidePhase 3Recruiting3002024-06-03
Diabetes Islet Preservation Immune TreatmentNCT02586831 · Camillo Ricordi and Jay SkylerExenatidePhase 1/Phase 2Withdrawn02024-06-01
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130 · Novo Nordisk A/SCagrilintidePhase 2Completed2702024-05-20
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 DiabetesNCT06403761 · Novo Nordisk A/SCagrilintidePhase 1Completed1582024-05-06
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting100002024-04-30
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660 · Eli Lilly and CompanyRetatrutidePhase 3Completed5372024-04-10
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.NCT06283641 · Novo Nordisk A/SLiraglutide—Completed3002024-04-08
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes MellitusNCT06235086 · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.DulaglutidePhase 3Completed6322024-04-08
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372 · Novo Nordisk A/SCagrilintidePhase 2Completed6262024-04-01
Use of Liraglutide in Children Aged 6 to 12 Years With Severe ObesityNCT07590219 · University of Sao Paulo General HospitalLiraglutidePhase 4Active not recruiting302024-03-30
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminNCT06323161 · Novo Nordisk A/SCagrilintidePhase 3Completed2742024-03-26
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943NCT06313528 · Eli Lilly and CompanyRetatrutidePhase 1Completed852024-03-20
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac SurgeryNCT06324461 · The University of Hong KongDulaglutidePhase 4Recruiting3722024-03-20
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT06323174 · Novo Nordisk A/SCagrilintidePhase 3Completed1892024-03-19
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting3202024-03-15
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGHNCT06003153 · Massachusetts General HospitalSemaglutidePhase 4Recruiting1252024-03-12
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightNCT06289504 · Novo Nordisk A/SCagrilintidePhase 1Completed342024-02-27
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body WeightNCT06207877 · Novo Nordisk A/SCagrilintidePhase 1Completed622024-02-23
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting12502024-02-21
A Study of How CagriSema Works on Appetite in People With Excess Body WeightNCT06267092 · Novo Nordisk A/SCagrilintidePhase 1Completed1642024-02-15
A Study of HS-20094 in Patients With T2DMNCT06901648 · Jiangsu Hansoh Pharmaceutical Co., Ltd.DulaglutidePhase 2Completed2752024-02-06
Effect of Liraglutide in Obese Women With Polycystic Ovary SyndromeNCT05965908 · Beni-Suef UniversityLiraglutidePhase 3Completed1502024-01-30
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory IssuesNCT06171152 · University of ChicagoLiraglutideEARLY_Phase 1Suspended302024-01-26
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969 · Novo Nordisk A/SCagrilintidePhase 3Completed10242024-01-16
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminNCT06192108 · Eli Lilly and CompanyOrforglipronPhase 3Completed9622024-01-10
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese ParticipantsNCT06186622 · Eli Lilly and CompanyOrforglipronPhase 1Completed502024-01-02
Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DMNCT06256419 · The Affiliated Hospital of Xuzhou Medical UniversityExenatide—Recruiting3002024-01-01
Pharmacological Treatment - An Overview of Its Role in Managing Childhood ObesityNCT07304141 · Göteborg UniversityLiraglutide—Completed1282023-12-20
Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes MellitusNCT06148649 · Dongguan HEC Biopharmaceutical R&D Co., Ltd.DulaglutidePhase 2Completed2342023-12-10
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightNCT06131437 · Novo Nordisk A/SCagrilintidePhase 3Completed8092023-11-27
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956 · Eli Lilly and CompanyTirzepatidePhase 2Recruiting14812023-11-17
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorNCT06109311 · Eli Lilly and CompanyOrforglipronPhase 3Completed5462023-11-10
Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese SubjectsNCT06247748 · Beijing Dongfang Biotech Co., Ltd.ExenatidePhase 1Completed282023-10-19
A Phase I Study of LY3502970 in Healthy ParticipantsNCT06085482 · Eli Lilly and CompanyOrforglipronPhase 1Completed102023-10-19
Semaglutide Therapy for Alcohol Reduction (STAR)NCT06015893 · National Institute on Drug Abuse (NIDA)SemaglutidePhase 2Recruiting802023-10-17
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT06075667 · Eli Lilly and CompanyTirzepatidePhase 3Active not recruiting1602023-10-16
Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesNCT05478707 · University of VirginiaDulaglutidePhase 2Suspended472023-10-05
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 DiabetesNCT06010004 · Eli Lilly and CompanyOrforglipronPhase 3Completed4012023-09-28
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 · Novo Nordisk A/SSemaglutideCagrilintidePhase 3Completed27342023-09-27
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT06045221 · Eli Lilly and CompanyOrforglipronPhase 3Completed16982023-09-22
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKDNCT07309094 · Cardenal Herrera UniversityLiraglutideDulaglutideExenatide—Recruiting2502023-09-15
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational DiabetesNCT05569772 · Universitaire Ziekenhuizen KU LeuvenSemaglutidePhase 3Recruiting2522023-09-14
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseNCT06039826 · Eli Lilly and CompanyRetatrutidePhase 1Completed462023-09-12
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic SurgeryNCT07374445 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolLiraglutidePhase 4Completed1002023-09-01
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection DevicesNCT06003465 · Eli Lilly and CompanyRetatrutidePhase 1Completed572023-08-29
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose WeightNCT05996848 · Novo Nordisk A/SCagrilintidePhase 3Completed3002023-08-15
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneNCT05971940 · Eli Lilly and CompanyOrforglipronPhase 3Completed5592023-08-09
A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)NCT05984238 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Semaglutide—Completed332023-08-03
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367 · Eli Lilly and CompanyRetatrutidePhase 3Completed4452023-08-01
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151 · Eli Lilly and CompanyRetatrutidePhase 2Completed1462023-07-20
A Study of LY3437943 in Healthy Participants With a High Body Mass IndexNCT05959096 · Eli Lilly and CompanyRetatrutidePhase 1Completed852023-07-18
A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionNCT05916560 · Eli Lilly and CompanyRetatrutidePhase 1Completed432023-07-13
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.NCT05936138 · Eli Lilly and CompanyOrforglipronPhase 1Completed242023-07-13
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting10002023-07-11
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066 · Eli Lilly and CompanyRetatrutidePhase 3Completed23352023-07-10
Cathelicidin LL-37 Relation to Potentially Malignant LesionsNCT06219330 · Fayoum UniversityLL-37—Completed452023-07-01
Preoperative Weight Loss for Open Abdominal Wall ReconstructionNCT05925959 · Benjamin T. MillerLiraglutide—Recruiting2582023-06-19
A Study of LY3502970 in Participants With Impaired and Normal Liver FunctionNCT05882032 · Eli Lilly and CompanyOrforglipronPhase 1Completed292023-06-13
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903 · Eli Lilly and CompanyOrforglipronPhase 3Active not recruiting31272023-06-05
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT05872620 · Eli Lilly and CompanyOrforglipronPhase 3Completed16132023-06-05
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 · Eli Lilly and CompanyRetatrutidePhase 3Active not recruiting19462023-05-30
Effects of GH and Lirglutide on AgRPNCT05681299 · Columbia UniversityLiraglutidePhase 4Recruiting402023-05-01
Comparing the Efficacy of tDCS and tRNS to Improve Reading Skills in Children and Adolescents With DyslexiaNCT05832060 · Bambino Gesù Hospital and Research InstituteSelank—Unknown242023-05-01
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese ParticipantsNCT05841238 · Eli Lilly and CompanyOrforglipronPhase 1Completed522023-04-26
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational DiabetesNCT05482789 · Maisa N. Feghali, MDExenatidePhase 4Recruiting132023-04-12
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2NCT05555589 · ReGenTree, LLCThymosin Beta-4Phase 3Recruiting702023-04-11
A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the BodyNCT05564104 · Novo Nordisk A/SCagrilintidePhase 1Completed322023-04-05
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightNCT05813925 · Novo Nordisk A/SCagrilintidePhase 3Completed3312023-04-03
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421 · Eli Lilly and CompanyOrforglipronPhase 3Completed27492023-04-03
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 · Novo Nordisk A/SCagrilintidePhase 3Active not recruiting71012023-03-01
Clinical Study of 18F-Exendin-4 in InsulinomaNCT07340437 · Sichuan Provincial People's HospitalExenatide—Completed202023-02-01
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightNCT05394519 · Novo Nordisk A/SCagrilintidePhase 3Completed12002023-02-01
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in AmericaNCT05579249 · Novo Nordisk A/SLiraglutidePhase 4Completed5002023-01-19
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DMNCT05680129 · Hangzhou Sciwind Biosciences Co., Ltd.DulaglutidePhase 3Completed6232023-01-10
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in IndiaNCT05659537 · Eli Lilly and CompanyDulaglutidePhase 4Completed2122022-12-29
Exenatide for Smoking Cessation and Prevention of Weight GainNCT05610800 · The University of Texas Health Science Center, HoustonExenatidePhase 2Completed1402022-12-07
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)NCT05564039 · Eli Lilly and CompanyDulaglutidePhase 4Completed2822022-11-30
Effects of Glucagon-like-Peptide-1 Analogues on SexualityNCT05598008 · University Hospital, Basel, SwitzerlandLiraglutide—Completed852022-11-25
A Trial to Determine the Efficacy and Safety of Presendin in IIHNCT05347147 · Invex Therapeutics Ltd.ExenatidePhase 3Terminated142022-11-18
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseNCT05616013 · Eli Lilly and CompanySemaglutidePhase 2Completed5072022-11-16
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal FunctionNCT05611957 · Eli Lilly and CompanyRetatrutidePhase 1Completed292022-11-16
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796 · Novo Nordisk A/SCagrilintidePhase 3Active not recruiting34002022-11-01
A Study of LY3437943 in Chinese Participants With Obesity Or OverweightNCT05548231 · Eli Lilly and CompanyRetatrutidePhase 1Completed322022-10-24
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy ParticipantsNCT05573230 · Eli Lilly and CompanyOrforglipronPhase 1Completed322022-10-17
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesNCT05313529 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolLiraglutide—Active not recruiting3962022-10-08
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesNCT05390892 · Brigham and Women's HospitalLiraglutideDulaglutidePhase 4Recruiting60002022-09-26
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection FractionNCT05371496 · Mayo ClinicSemaglutidePhase 4Enrolling by invitation812022-09-06
The Impact of Ibutamoren on Nonalcoholic Fatty Liver DiseaseNCT05364684 · Massachusetts General HospitalMK-677Phase 2Completed122022-08-10
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy ParticipantsNCT05469126 · Eli Lilly and CompanyOrforglipronPhase 1Completed262022-08-01
Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial InfarctionNCT05984134 · Beijing Northland Biotech. Co., Ltd.Thymosin Beta-4Phase 2Completed902022-07-15
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsNCT05445232 · Eli Lilly and CompanyRetatrutidePhase 1Completed322022-07-08
Young Adults With Early-onset Obesity Treated With SemaglutideNCT05574439 · Signe TorekovSemaglutidePhase 4Completed2462022-05-30
A Study of LY3502970 in Healthy Overweight and Obese ParticipantsNCT05313802 · Eli Lilly and CompanyOrforglipronPhase 1Completed722022-05-26
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)NCT05356104 · Chinese University of Hong KongExenatidePhase 2Recruiting1102022-05-25
A Study of Two Different Formulations of LY3502970 in Healthy ParticipantsNCT05341089 · Eli Lilly and CompanyOrforglipronPhase 1Completed392022-05-17
Lifestyle Counseling and Medication for Adolescent Weight ManagementNCT04873245 · University of MinnesotaSemaglutidePhase 2Completed1202022-03-15
Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney DiseaseNCT05254418 · Vanderbilt University Medical CenterDulaglutidePhase 2Completed72022-03-15
Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes MellitusNCT05662189 · Azienda Ospedaliero-Universitaria di ParmaExenatide—Recruiting702022-03-15
Adiponectin in Patients With Metabolic DisordersNCT07539584 · Moscow Regional Research and Clinical Institute (MONIKI)Liraglutide—Completed1302022-03-01
Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 DiabetesNCT04307797 · Cambridge University Hospitals NHS Foundation TrustExenatidePhase 4Completed102022-01-18
A Multiple-Dose Study of LY3502970 in Healthy ParticipantsNCT05110794 · Eli Lilly and CompanyOrforglipronPhase 1Completed342021-11-05
A Multiple Dose Study of LY3502970 in Healthy ParticipantsNCT05051566 · Eli Lilly and CompanyOrforglipronPhase 1Completed262021-09-16
Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)NCT04897802 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauExenatidePhase 4Completed422021-09-13
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 DiabetesNCT04982575 · Novo Nordisk A/SCagrilintidePhase 2Completed922021-08-02
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyNCT05220917 · Brigham and Women's HospitalLiraglutideDulaglutideExenatide—Active not recruiting7814302021-08-01
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose IntoleranceNCT04731272 · University of PennsylvaniaDulaglutidePhase 2Recruiting302021-07-16
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or ObesityNCT04940078 · Novo Nordisk A/SCagrilintidePhase 1Completed402021-07-07
Comparison of Type 2 Diabetes Pharmacotherapy RegimensNCT05073692 · Kaiser PermanenteExenatide—Completed2419812021-07-01
Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNCT04952779 · Novo Nordisk A/SLiraglutide—Completed7502021-06-02
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)NCT04823208 · Eli Lilly and CompanyRetatrutidePhase 1Completed642021-05-24
A Study of LY3437943 in Participants Who Have Obesity or Are OverweightNCT04881760 · Eli Lilly and CompanyRetatrutidePhase 2Completed3382021-05-20
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)NCT04777396 · Novo Nordisk A/SSemaglutidePhase 3Completed18402021-05-18
A Study of LY3437943 in Participants With Type 2 DiabetesNCT04867785 · Eli Lilly and CompanyRetatrutidePhase 2Completed2812021-05-13
Exenatide-test for Diagnosing Endogenous Hyperinsulinemic HypoglycemiaNCT04909333 · University Hospital, Basel, SwitzerlandExenatide—Completed292021-04-29
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)NCT04822181 · Novo Nordisk A/SSemaglutidePhase 3Active not recruiting12052021-04-01
Peri-implant Vitamin D and Cathelicidin (LL-37) LevelsNCT06867250 · Altinbas UniversityLL-37—Completed332021-04-01
Combined Active Treatment in Type 2 Diabetes With NASHNCT04639414 · German Diabetes CenterSemaglutidePhase 4Completed1922021-03-26
SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityNCT04775082 · Novo Nordisk A/SLiraglutidePhase 3Active not recruiting782021-03-04
Cathelicidin LL-37 Levels in the GCF and the Saliva of Smokers and Non-smokers With Stage III,IV PeriodontitisNCT04861493 · Cairo UniversityLL-37—Completed602021-02-23
Brain Activation and Satiety in Children 2NCT04520490 · Seattle Children's HospitalExenatidePhase 3Active not recruiting632021-01-28
Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionNCT05485818 · Beijing Northland Biotech. Co., Ltd.Thymosin Beta-4Phase 2Completed622020-11-23
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic SyndromeNCT04575844 · University of VirginiaLiraglutidePhase 4Recruiting802020-11-01
A Study of LY3502970 in Participants With Type 2 DiabetesNCT04426474 · Eli Lilly and CompanyOrforglipronPhase 1Completed682020-10-08
Exenatide Once-weekly as a Treatment for Multiple System AtrophyNCT04431713 · University College, LondonExenatidePhase 2Completed502020-09-16
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · Eli Lilly and CompanyTirzepatideDulaglutidePhase 3Completed132992020-05-29
A Clinical Study of NLY01 in Patient's With Early Parkinson's DiseaseNCT04154072 · Neuraly, Inc.ExenatidePhase 2Completed2552020-02-27
Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's DiseaseNCT04232969 · University College, LondonExenatidePhase 3Completed1942020-01-20
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)NCT04143802 · Eli Lilly and CompanyRetatrutidePhase 1Completed722019-12-18
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)NCT03884075 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)SemaglutidePhase 2Recruiting1042019-07-24
A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial InfarctionNCT01311518 · RegeneRx Biopharmaceuticals, Inc.Thymosin Beta-4Phase 2Withdrawn02019-07
A Study of LY3502970 in Healthy ParticipantsNCT03929744 · Eli Lilly and CompanyOrforglipronPhase 1Completed1332019-06-12
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3NCT03937882 · ReGenTree, LLCThymosin Beta-4Phase 3Completed7002019-05-24
Imaging Pituitary ActiVation by ExendinNCT03923114 · Radboud University Medical CenterExenatide—Completed202019-05-23
Liraglutide Effect in Atrial FibrillationNCT03856632 · University of MiamiLiraglutidePhase 4Active not recruiting602019-03-18
A Safety Study of LY3437943 Given as a Single Injection in Healthy ParticipantsNCT03841630 · Eli Lilly and CompanyRetatrutidePhase 1Completed452019-03-13
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related DiseaseNCT06725693 · Tianjin Medical UniversityExenatide—Recruiting5002019-02-01
Growth Hormone Dynamics and Cardiac Steatosis in HIVNCT03826160 · Massachusetts General HospitalTesamorelin—Completed232019-01-30
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular RiskNCT03375788 · Massachusetts General HospitalSermorelinTesamorelinPhase 2Completed512019-01-17
A Phase 1b Study of Thymosin Beta 4 in Healthy VolunteersNCT04555850 · Beijing Northland Biotech. Co., Ltd.Thymosin Beta-4Phase 1Completed302018-07-30
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve InjuryNCT03150511 · Johns Hopkins UniversityTesamorelinPhase 2Recruiting362018-06-01
Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance ImagingNCT03498001 · Centre Hospitalier Universitaire DijonLiraglutideDulaglutide—Completed422018-04-16
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular DiseaseNCT03492580 · Janssen Research & Development, LLCDulaglutideExenatide—Completed7145822018-02-22
Body Composition and Adipose Tissue in HIVNCT03226821 · Columbia UniversityTesamorelinPhase 4Terminated62018-02-07
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their CombinationNCT03878706 · University of AthensLiraglutideMOTS-c—Recruiting2402017-11-03
The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive ImpairmentNCT02553603 · The University of Texas Medical Branch, GalvestonSermorelinTesamorelinPhase 1Completed222017-07-18
A Phase 1a Study of Thymosin Beta 4 in Healthy VolunteersNCT04555824 · Beijing Northland Biotech. Co., Ltd.Thymosin Beta-4Phase 1Completed542017-07-17
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected PersonsNCT02572323 · University of California, San DiegoTesamorelinPhase 2Completed732017-02-15
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma TherapyNCT02860923 · University Hospital, BordeauxExenatidePhase 3Completed422017-01-11
Study of Intranasal Octreotide (DP1038) in Healthy Adult VolunteersNCT03031535 · Dauntless PharmaceuticalsSermorelinPhase 1Completed322017-01
Saxenda: Underlying Mechanisms and Clinical OutcomesNCT02944500 · Beth Israel Deaconess Medical CenterLiraglutidePhase 4Active not recruiting282016-11
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2NCT02974907 · ReGenTree, LLCThymosin Beta-4Phase 3Completed6012016-11
Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current InsomniaNCT02931474 · National Institute of Nursing Research (NINR)TesamorelinPhase 2Withdrawn02016-10-06
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.NCT02806414 · University of California, San DiegoLL-37Phase 1/Phase 2Completed252016-07
Pharmacogenomics of GLP1 Receptor AgonistsNCT05762744 · University of Maryland, BaltimoreExenatidePhase 1Terminated632016-06-01
Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian ResponseNCT02736591 · Cairo UniversitySermorelinPhase 3Unknown2102016-06
Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican PatientsNCT02773355 · Novo Nordisk A/SLiraglutide—Completed272016-05-16
GLP-1 and Hyperoxia for Organ Protection in Heart SurgeryNCT02673931 · Rigshospitalet, DenmarkExenatide—Active not recruiting14002016-02
Therapeutic Benefit of Preoperative Supplemental Vitamin D in Patients Undergoing Major Surgical Procedures.NCT02138591 · University of Missouri, Kansas CityLL-37Phase 3Withdrawn02016-02
Cohort Of DEafness-gene ScreeningNCT06133946 · Affiliated Hospital of Nantong UniversityMOTS-c—Active not recruiting359202016-01-01
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal SyndromeNCT02251431 · Baylor Research InstituteExenatidePhase 3Completed572015-11
PCO-02 - Safety and Pharmacokinetics TrialNCT02637284 · PharmaCotherapia d.o.o.BPC-157Phase 1Unknown422015-10
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1NCT02597803 · ReGenTree, LLCThymosin Beta-4Phase 2/Phase 3Completed3172015-09
Tesamorelin Effects on Liver Fat and Histology in HIVNCT02196831 · Massachusetts General HospitalSermorelinTesamorelin—Completed612015-07-01
Estradiol-Receptor Blockade in Older Men and WomenNCT02271282 · Mayo ClinicSermorelinPhase 1Completed402014-12
Liver and Fat Regulation in Overweight Adolescent GirlsNCT02157974 · University of Colorado, DenverExenatidePhase 2/Phase 3Completed922014-08
Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 DiabetesNCT02674893 · Centre Hospitalier Universitaire DijonLiraglutidePhase 4Terminated482014-02-04
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CADNCT04027712 · University of AthensMOTS-c—Unknown1202014-01-01
Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD)NCT02507245 · Stefania La Grutta, MDSermorelin—Completed482014-01
Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone AnalogueNCT01632592 · Massachusetts General HospitalSermorelinTesamorelin—Withdrawn02014-01
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesNCT01794143 · GRADE Study GroupLiraglutidePhase 3Completed78502013-05
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®NCT01579695 · TheratechnologiesTesamorelin—Terminated3912013-02
Effects of Transcranial Magnetic Stimulation on Object RecognitionNCT01747200 · National Institute of Neurological Disorders and Stroke (NINDS)Selank—Completed132012-11-16
Effect of Liraglutide on Fatty Liver Content and Lipoprotein MetabolismNCT02721888 · Centre Hospitalier Universitaire DijonLiraglutidePhase 4Terminated1272012-07-10
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®NCT01591902 · TheratechnologiesTesamorelinPhase 4Terminated1292012-06
Egrifta Replacement and Sleep Disordered BreathingNCT01788462 · Johns Hopkins UniversityTesamorelin—Withdrawn02012-05
Effects of Smoking and Vitamin D3 on the Levels of Human Cathelicidin Peptide LL-37NCT03923218 · Gazi UniversityLL-37—Completed602011-12
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle WastingNCT01388920 · TheratechnologiesTesamorelinPhase 2Terminated32011-09
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry EyeNCT01387347 · ReGenTree, LLCThymosin Beta-4Phase 2Completed722011-08
Effects of Aminocaproic Acid (ACA) on Rosacea-specific InflammationNCT01398280 · University of California, San DiegoLL-37EARLY_Phase 1Completed152011-07
Vitamin D in Ventilated ICU PatientsNCT01372995 · Emory UniversityLL-37Phase 2Completed312011-07
Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the ElderlyNCT01410799 · University of PennsylvaniaSermorelinPhase 2Terminated132011-05
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal FunctionNCT01280344 · Helsinn Therapeutics (U.S.), IncIpamorelinPhase 2Completed3202011-04
Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry EyeNCT01393132 · Michigan Cornea Consultants, PCThymosin Beta-4Phase 2Completed92011-03
VRS-317 in Adult Subjects With Growth Hormone DeficiencyNCT01359488 · Versartis Inc.SermorelinPhase 1Completed502011-03
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese DiabeticsNCT02042664 · Assistance Publique Hopitaux De MarseilleExenatidePhase 3Completed442011-01
Effects of Growth Hormone Releasing Hormone in HIVNCT01263717 · Massachusetts General HospitalSermorelinTesamorelin—Completed542010-12
Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 SubjectsNCT01343641 · University of VirginiaMK-677Phase 2Withdrawn02009-03
Effects of Short-term Growth Hormone in HIV-infected PatientsNCT00795210 · Massachusetts General HospitalSermorelinTesamorelin—Completed252009-02
Effect of Short Term Growth Hormone Releasing Hormone in Healthy MenNCT00850564 · Massachusetts General HospitalSermorelinTesamorelin—Completed152009-02
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DMNCT01107717 · The University of Texas Health Science Center at San AntonioExenatidePhase 4Completed3182009-01
Vitamin D in Active Tuberculosis (TB) StudyNCT00788320 · Atlanta VA Medical CenterLL-37—Withdrawn02008-10
Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are ObeseNCT00675506 · Massachusetts General HospitalSermorelinTesamorelinPhase 2Completed602008-07
Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive PatientsNCT02012556 · TheratechnologiesSermorelinTesamorelinPhase 1Completed182008-05
A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy VolunteersNCT00743769 · RegeneRx Biopharmaceuticals, Inc.Thymosin Beta-4Phase 1Withdrawn02008-04
Safety and Efficacy of Ipamorelin for Management of Post-Operative IleusNCT00672074 · Helsinn Therapeutics (U.S.), IncIpamorelinPhase 2Completed1172008-04
Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the ElderlyNCT00807365 · Johns Hopkins UniversitySermorelinPhase 2Terminated52007-12-17
A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal WoundsNCT00598871 · ReGenTree, LLCThymosin Beta-4Phase 2Terminated122007-12
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) ProtocolNCT00679042 · CellTrans Inc.ExenatidePhase 3Active not recruiting212007-09-05
TH9507 Extension Study in Patients With HIV-Associated LipodystrophyNCT00608023 · TheratechnologiesSermorelinTesamorelinPhase 3Completed2632007-08
Sexually Dimorphic Effects of GHRH in Adult Growth Hormone TestingNCT00324064 · Children's Mercy Hospital Kansas CitySermorelin—Completed902007-07
Adult Growth Hormone Deficiency and Cardiovascular RiskNCT00720902 · Columbia UniversitySermorelinPhase 4Terminated72007-02
GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial EmulationNCT07677865 · West China HospitalSemaglutideTirzepatideLiraglutide—Completed2138912007-01-01
Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD PatientsNCT00395291 · University of VirginiaMK-677—Completed492006-08
Study of Thymosin Beta 4 in Patients With Venous Stasis UlcersNCT00832091 · RegeneRx Biopharmaceuticals, Inc.Thymosin Beta-4Phase 2Completed722006-07
Study of Thymosin Beta 4 in Patients With Pressure UlcersNCT00382174 · RegeneRx Biopharmaceuticals, Inc.Thymosin Beta-4Phase 2Completed722006-05
A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis BullosaNCT00311766 · RegeneRx Biopharmaceuticals, Inc.Thymosin Beta-4Phase 2Terminated302006-02
SMART: Somatotrophics, Memory, and Aging Research TrialNCT00257712 · University of WashingtonSermorelinTesamorelinPhase 2Completed1512006-02
A Study to Evaluate CJC 1295 in HIV Patients With Visceral ObesityNCT00267527 · ConjuChemCJC-1295Phase 2Terminated1202005-12
Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)NCT00128115 · Merck Sharp & Dohme LLCMK-677Phase 2Terminated832005-09
Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of FibromyalgiaNCT00116129 · Bennett, Robert, M.D.MK-677Phase 2Completed642005-07
TH9507 in Patients With HIV-Associated LipodystrophyNCT00123253 · TheratechnologiesSermorelinTesamorelinPhase 3Completed4122005-06
The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart FailureNCT00791843 · University of PennsylvaniaSermorelinPhase 2Completed32004-03
Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone DeficiencyNCT01060488 · Merck KGaA, Darmstadt, GermanySermorelinPhase 3Completed692004-01
Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)NCT00074529 · Merck Sharp & Dohme LLCMK-677Phase 2Completed5122003-10
Safety Study of TH9507 in Subjects With Stable, Type 2 DiabetesNCT01264497 · TheratechnologiesTesamorelinPhase 2Completed552002-02
Diagnosing Adult Growth Hormone DeficiencyNCT03018886 · Helsinki University Central HospitalSermorelin—Completed1602001-05
Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older AdultsNCT00474279 · University of VirginiaMK-677Phase 1/Phase 2Completed721998-07
Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep DisturbancesNCT00000380 · University of WashingtonSermorelin—Completed—1996-06
Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in AcromegalyNCT00004332 · National Center for Research Resources (NCRR)Sermorelin—Completed1481993-05
Provide Pre-approval Expanded Access of LY3437943NCT07629401 · Eli Lilly and CompanyRetatrutide—Available——

Trial data sourced from ClinicalTrials.gov(U.S. National Library of Medicine), a public-domain registry. Synptide adds the compound tagging and grouping. Registry data can lag real-world status — always confirm on the source record before relying on it.